Overview

Phase 1 Study of CT-996 in Overweight/Obese Participants and Patients With Type 2 Diabetes Mellitus

Status:
Not yet recruiting

Trial end date:
2024-11-01

Target enrollment:

Participant gender:

Summary

A study designed to assess the safety and tolerability, pharmacokinetics, and pharmacodynamics of CT-996 in overweight/obese participants and participants with T2DM.

Phase:

Phase 1

Details

Lead Sponsor:

Carmot Therapeutics, Inc.

Collaborator:

Carmot Australia First Pty Ltd